Results 91 to 100 of about 1,942,013 (293)

Cutaneous Eruptions Associated With Tumour Infiltrating Lymphocyte Therapy: A Case Series

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Tumour‐infiltrating lymphocyte (TIL) therapy is a newly emerged effective treatment for advanced melanoma refractory to immune checkpoint inhibitors; however, its cutaneous adverse effects remain uncharacterized. We present the first case series describing dermatologic adverse effects associated with TIL therapy for malignant melanoma in five ...
Shannon C. Lyden   +9 more
wiley   +1 more source

Subcorneal Pustular Dermatosis, a Systematic Review and Pooled Analysis of a Rare and Underdiagnosed Disease

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Subcorneal pustular dermatosis (SPD), or Sneddon–Wilkinson disease, is a rare, relapsing pustular skin condition of unknown cause, characterised by subcorneal pustules. Objectives To summarise the demographic, clinical, histopathological, management and disease course of SPD.
Mason H. Crossman   +5 more
wiley   +1 more source

Fixed Drug Eruption with Pigmentation Induced by Etoricoxib: A Case Report

open access: yesIatreia
Fixed drug eruption with pigmentation is characterized by the appearance of erythematous or bullous lesions following the ingestion of certain medications.
Dextre-Vilchez, Sergio Armando   +1 more
doaj   +1 more source

Pseudoephedrine-induced Fixed Drug Eruption in a Scuba Diver With Recurrent Palmoplantar Exfoliation [PDF]

open access: yesJournal of Preventive Medicine and Public Health
This report presents a case of pseudoephedrine-induced non-pigmented bullous fixed drug eruption (NBFDE) manifesting as recurrent palmoplantar exfoliation in a scuba diver.
Pimpreeya Kajornchaikul   +2 more
doaj   +1 more source

Multiple fixed drug eruptions [PDF]

open access: yes
Fixed drug eruptions (FDE) are a type of hypersensitivity reaction that occurs in response to certain medications, typically reappearing at the same site when the causative drug is reintroduced.
Muzaffer, Maliha   +2 more
core   +1 more source

Pembrolizumab‐Induced Subacute Cutaneous Lupus Erythematosus: A Case Report

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Subacute cutaneous lupus erythematosus (SCLE) is an increasingly recognized cutaneous immune‐related adverse event of immune checkpoint inhibitors. We report an 83‐year‐old woman who developed pruritic annular and polycyclic plaques 10 weeks after starting pembrolizumab for oropharyngeal squamous cell carcinoma.
Sebastiano Posenato   +5 more
wiley   +1 more source

Clinical study and skin tests of patients with drug eruptions

open access: yes, 2018
Background: Drug reactions are common problems in hospital inpatients and outpatients. Reliable diagnosis is essential but often difficult. Objective: This study attempts to define the clinical features and causative drugs in the patients with drug ...
명기범, 최혜영
core   +1 more source

Iododerma after Lugol use for pre-operative preparation of thyroidectomy

open access: yesRevista da Sociedade Portuguesa de Dermatologia e Venereologia, 2022
A 35-year-old man with hyperthyroidism reported the sudden occurrence of ulcerated and painful oral lesions, painful ulcerative-necrotic lesions on the face, trunk, upper and lower limbs and purpuric circinate lesions on the scalp, 6 days after starting ...
David Almeida   +6 more
doaj  

Home - About - Disclaimer - Privacy